Company Overview
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -50.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -23.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -23.77% |
| 1 Year: | -50.60% |
Stock Price Performance
| 1 Year: | +46.39% |
| 6 Months: | +63.09% |
| 3 Months: | +49.08% |
| 1 Month: | +18.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -23.8% CAGR over 5 years.
- Trading 35.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Real Estate).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RFL Rafael Holdings, Inc. | 2.43 | -3.38 | $124.45M | 0.00% | -100.12% | -37.59% | -23.77% | - |
| 2 | WELL Welltower Inc. SPXR3K | 236.17 | 105.91 | $170.18B | 1.46% | 0.54% | 3.84% | 22.26% | 11.10% |
| 3 | PLD Prologis, Inc. SPXR3K | 138.48 | 30.84 | $131.60B | 3.17% | - | 7.75% | 16.83% | 39.42% |
| 4 | EQIX Equinix, Inc. SPXR3K | 1,041.21 | 67.13 | $102.74B | 1.98% | 5.42% | 10.73% | 17.43% | 17.11% |
| 5 | AMT American Tower Corporation SPXR3K | 175.73 | 24.14 | $81.88B | 3.97% | 8.76% | 33.91% | 12.41% | 25.08% |
| 6 | DLR Digital Realty Trust, Inc. SPXR3K | 189.50 | 92.44 | $70.30B | 2.65% | - | 2.91% | 15.18% | 18.41% |
| 7 | SPG Simon Property Group, Inc. SPXR3K | 211.88 | 14.95 | $68.55B | 4.35% | - | 120.51% | 3.14% | 14.02% |
| 8 | O Realty Income Corporation SPXR3K | 61.02 | 44.54 | $57.74B | 5.68% | - | 3.23% | 24.73% | 13.04% |
| 9 | PSA Public Storage SPXR3K | 301.60 | 28.81 | $56.35B | 3.99% | - | 21.93% | 5.67% | 7.85% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Oct 2021 | Jan 2022 | Apr 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.34M | 1.28M | 1.60M | 1.11M | 956.00K | 1.09M | 1.22M | 1.14M | 1.02M | 1.38M | 1.21M | 1.24M | 1.22M | 1.05M | 959.00K | 990.00K | 191.00K | 74.00K | 76.00K | 70.00K | 70.00K | 71.00K | 68.00K | 68.00K | 336.00K | 128.00K | 77.00K | 362.00K | - | 240.00K | 211.00K | 179.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.00K | 40.00K | - | 9.00K | 12.00K | 8.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00K | 322.00K | - | 231.00K | 199.00K | 171.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.63M | 6.24M | - | 10.37M | 6.85M | 7.04M |
| Operating Income | 127.00K | -164.00K | 100.00K | -1.05M | -816.00K | -731.00K | -1.24M | -1.12M | -1.41M | -1.42M | -1.54M | -1.91M | -1.97M | -2.49M | -10.82M | -3.48M | -49.54M | -1.60M | -4.69M | -5.14M | -4.26M | -3.03M | -2.48M | -3.14M | -93.16M | -3.84M | -3.59M | -5.91M | - | -10.14M | -6.66M | -6.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.05M | -6.24M | - | -9.58M | -6.06M | -2.84M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 163.00K | 165.00K | - | 160.00K | 161.00K | 6.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.31M | -6.46M | - | -9.79M | -6.28M | -2.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00K | -2.41M | - | 10.00K | 48.00K | 6.00K |
| Net Income | 166.00K | -65.00K | -91.00K | -9.33M | -546.00K | -531.00K | -635.00K | -481.00K | -1.02M | -1.00M | -1.60M | -1.25M | -2.16M | -1.43M | -8.24M | -2.65M | -128.87M | -2.06M | -5.55M | 1.59M | -3.25M | -1.44M | -3.64M | 6.05M | -32.35M | -9.01M | -4.64M | -4.78M | -290.00K | -9.82M | -6.42M | -4.23M |
| Diluted EPS | 0.01 | -0.01 | -0.01 | 0.01 | -0.07 | -0.06 | -0.05 | -0.75 | - | - | - | - | - | - | - | - | -5.91 | -0.12 | -0.28 | 0.07 | -0.14 | -0.06 | -0.15 | 0.25 | -1.36 | -0.37 | -0.19 | -0.19 | - | -0.19 | -0.13 | -0.08 |
| R&D Expense | - | - | - | - | - | - | - | 373.00K | 276.00K | 300.00K | 245.00K | 448.00K | 634.00K | 515.00K | 1.57M | 1.26M | 2.15M | 3.33M | 1.41M | 2.08M | 2.23M | 740.00K | 489.00K | 612.00K | 1.53M | 1.33M | 947.00K | 3.00M | 232.00K | 7.48M | 4.53M | 4.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.59M | 5.62M | 4.37M | 4.93M | 4.91M | 802.00K | 410.00K | 279.00K | 637.00K | - |
| Cost of Revenue | - | - | - | - | - | - | - | 0 | 154.00K | - |
| Gross Profit | - | - | - | - | - | - | - | 279.00K | 483.00K | - |
| Operating Expenses | - | - | - | - | - | - | 60.89M | 15.32M | 103.11M | - |
| Operating Income | 1.19M | 221.00K | -3.84M | -6.70M | -8.46M | -28.20M | -60.48M | -15.04M | -102.63M | - |
| EBITDA | - | - | - | - | - | - | -139.89M | -8.67M | -66.79M | - |
| Interest Expense | - | - | - | - | - | - | 6.00K | 0 | 248.00K | - |
| Pretax Income | - | - | - | - | - | - | -139.97M | -8.74M | -67.26M | - |
| Tax Provision | - | - | - | - | - | - | 0 | -255.00K | -2.68M | - |
| Net Income | 710.00K | 138.00K | -11.65M | -4.69M | -10.75M | -23.06M | -124.66M | -1.88M | -34.41M | - |
| Diluted EPS | 0.06 | 0.01 | -0.93 | - | - | -1.49 | -6.22 | -0.08 | -1.43 | -1.04 |
| R&D Expense | - | - | 995.00K | 1.03M | 2.39M | 4.91M | 8.74M | 6.31M | 4.17M | 12.82M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2015 | Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 86.20M | 116.92M | 142.14M | 136.35M | 154.06M | 118.32M | 98.83M | 96.83M | 114.11M |
| Current Assets | - | - | - | - | - | - | - | 108.35M | 82.94M | 72.50M | - |
| Cash & Equivalents | 5.65M | 2.34M | 11.76M | 15.80M | 12.02M | 6.21M | 7.85M | 26.54M | 21.50M | 2.67M | 52.77M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | 157.00K | 213.00K | 426.00K | - |
| Total Liabilities | - | - | 24.13M | 1.35M | 17.38M | 5.82M | 17.35M | 21.11M | 2.20M | 10.57M | 15.74M |
| Current Liabilities | - | - | 363.00K | 891.00K | 1.43M | 5.73M | 17.30M | 21.03M | 2.15M | 7.51M | 11.60M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 73.00K | - |
| Total Debt | - | - | - | - | - | - | - | 15.00M | - | 2.39M | - |
| Total Equity | 48.11M | 48.81M | 52.74M | 106.70M | 110.98M | 116.80M | 122.29M | 100.52M | 100.29M | 82.19M | 94.39M |
| Shares Outstanding | - | - | - | - | - | - | - | 24.83M | 24.77M | 25.06M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 72.00K | -1.62M | -1.81M | -3.13M | -4.67M | -15.60M | -26.08M | -10.89M | -7.80M | -18.92M |
| Investing Cash Flow | -3.65M | -11.22M | 4.11M | -31.24M | -1.03M | -8.17M | -63.80M | 21.21M | -10.82M | 44.03M |
| Financing Cash Flow | 265.00K | 22.26M | 1.75M | 30.89M | -96.00K | 30.30M | 103.86M | -15.22M | -179.00K | 24.83M |
| Capital Expenditure | -1.55M | -1.82M | -710.00K | -399.00K | -534.00K | -206.00K | -2.00K | - | -178.00K | -4.00K |
| Free Cash Flow | -1.48M | -3.44M | -2.52M | -3.53M | -5.20M | -15.81M | -26.08M | -10.89M | -7.98M | -18.93M |
| Net Change in Cash | - | - | - | - | - | - | 13.99M | -4.89M | -18.80M | - |
Ratios (Annual)
Figures in %.
| Metric | Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 100.0% | 75.8% | - |
| Operating Margin % | 21.3% | 3.9% | -87.9% | -135.8% | -172.4% | -3,516.1% | -14,750.5% | -5,391.8% | -16,111.0% | - |
| Net Margin % | 12.7% | 2.5% | -266.5% | -95.2% | -219.0% | -2,875.4% | -30,404.4% | -672.4% | -5,401.9% | - |
| ROE % | 1.5% | 0.3% | -10.9% | -4.2% | -9.2% | -18.9% | -124.0% | -1.9% | -41.9% | - |
| ROCE % | - | 0.3% | -3.3% | -4.8% | -6.5% | -20.6% | -62.2% | -15.6% | -114.9% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.67% | 1.37M | $2.80M |
| 2 | Geode Capital Management, LLC | 0.84% | 429.88K | $881.25K |
| 3 | Blackrock Inc. | 0.76% | 390.07K | $799.64K |
| 4 | Dimensional Fund Advisors LP | 0.54% | 278.91K | $571.76K |
| 5 | Vanguard Fiduciary Trust Co | 0.40% | 206.52K | $423.37K |
| 6 | IEQ Capital, LLC | 0.32% | 164.96K | $338.17K |
| 7 | State Street Corporation | 0.31% | 157.27K | $322.40K |
| 8 | Kahn Brothers Group Inc. | 0.29% | 150.49K | $308.51K |
| 9 | Jane Street Group, LLC | 0.22% | 112.72K | $231.07K |
| 10 | Wells Fargo & Company | 0.20% | 103.59K | $212.36K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RFL
Rafael Holdings, Inc. Reports Q3 Fiscal 2026 Financial Results and Progress on Phase 3 TransportNPC™ Trial - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPWi16WlJKcFB3bUZ2QThvMHpjb2poVTZSOTVLeDZIdVh0cFJPMm9obGtYSVBtdnpGVnNjZE1QWERqellWUlZrVzZzcjd3aHBFREE1YVNTRmNYRGxlMXByeWJRMXllbjNIaDNoYzQzMjF1TDQzSzFWRVduLVF3YWh6WWxURnNjUnk1Mnp0Mn…
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNcDl2NzFaSmlhSXdYTjFKU2h0ZFdCTWptUmVXcTE4OF9ZcnNQZTh1Qk5nR2NORHZZRXZSTTNpekZDU0lTcWJSZlM1QXVJUXU0NlRnb3dZcEQwNmNtcU9uWnJ6RkpRbDZ6S3dqVVZsSVVqRHg3U09yRGQ0aGJCd3ppZmduZEpKWTBBN2hoZ0…
Price to earnings forward of Ramboda Falls PLC – CSELK:RFL.N0000 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNLUlMc0l5YW13SUFvQmEzQ3lHNkthQzR3UTFHaV8wYzZMMnY4WnRfLTJZNkYzMktJdUNmMVZZNVdETTg4b0M3YUZTZUpYei0yZk9iZ2dnYk8zbDVBVjhhYmVPMjJWOUhOdmNfNWh4TFRvN1ZvZEhuU09YclJ4MXczUFZHelRLb0djUDQxay…
Rafael Holdings completes phase 3 NPC disease trial enrollment - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdHhNSDMydEhfaTRibUluNnZhQ0dSMVYta24xNkdnYmtDMm5QdHFydWVnaXdWcEpSMUtRVFF2UnBVNFU4MWxHcW1oWDNIRXZVSTdVd2RvamZiYV9MODJjMExqQXd4dDRhcWVpT2lkR3phckM3bTdNMHB1aWxHRHJLbFJPNmtocnhKbTJidD…
Rafael Holdings Inc. Class B (RFL) Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQRUw0a2xqU1dVUDh1WUlWTm5pc2owRjNjSzdyc1MtaWt3VVA3UTdWWkk4WWg4V3NaYTRmOGxkOGNIdGd0aG9XcU9vWVFaNE4zbXRUZlZRd2tySWUtVm1OSG0xc3ZaMjF2UHpMTGhGNkRZeTg0QUpfMTI4QkFEWWtHMk1MQ0dhUC1tcGhRNU…
Rafael Holdings Inc (RFL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9LR0Q1VXN2T1VNTXZ1dEpVU08xYnhLMWNpbDNvUVZLTnVaaTJYMUpHWUplTmh3cDRkSVFmTWZDWUlsems5UkF3dkRqY19UYnFGMDdsVjliVXR2cGx5anZUT0pTZmFmZw?oc=5" target="_blank">Rafael Holdings Inc (RFL) Sha…
RFL — Frequently Asked Questions
What is the current share price of Rafael Holdings, Inc. (RFL)?
As of 2026-09-19 21:16 PDT, Rafael Holdings, Inc. (RFL) trades at $2.43 on NYSE. Its 52-week range is $1.16 to $3.78.
What is the market capitalisation of RFL?
Rafael Holdings, Inc. (RFL) has a market capitalisation of $124.45M on NYSE.
What is the P/E ratio of RFL?
RFL trades at a trailing price-to-earnings (P/E) ratio of -3.38. The industry average P/E is 23.49. Its price-to-book (P/B) ratio is 1.41.
What is the return on equity (ROE) of RFL?
RFL has a return on equity (ROE) of -37.59%. Its return on capital employed (ROCE) is -100.12%.
Is RFL a good stock to buy?
This page provides a data-driven analysis of Rafael Holdings, Inc. (RFL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.